+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying cryoglobulinemic vasculitis CV, a rare and serious immune system disorder that causes inflammation of blood vessels and can affect the skin, joints, kidneys, nerves, and other organs. This trial focuses on patients with active non-infectious CV who have not responded well to or cannot tolerate the current standard treatment Rituximab. The study aims to evaluate the safety and effectiveness of a different antibody treatment called Obinutuzumab in these patients. Participants will receive Obinutuzumab through an intravenous infusion at a dose of 1000 milligrams given at the start of the study and again two weeks later. This treatment is being assessed as a potential new option for CV patients who have limited choices due to resistance or intolerance to Rituximab. The trial is conducted as a single-arm study, meaning all participants receive Obinutuzumab, and it is designed as a phase 2 proof-of-concept study. During the study, participants will be monitored regularly for clinical response, side effects, and changes in disease activity using various clinical and laboratory tests over several months. Key outcomes include the rate of complete clinical response at 6 months, safety events up to 48 weeks, and longer-term measures of disease relapse and survival up to almost three years. Participants will undergo assessments including physical exams, laboratory tests, and disease activity scores to track progress and safety throughout the trial.

Age: 18Years +All GendersPhase 2
25 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
E

Actively Recruiting

Researchers are evaluating the use of circulating tumour DNA ctDNA analysis to detect early molecular relapse in patients with estrogen receptor positive ER and HER2 negative breast cancer who are undergoing adjuvant endocrine therapy. This trial aims to determine if treatment with palbociclib plus fulvestrant can delay or prevent relapse in patients who show positive ctDNA results. The study is a Phase 2, multi-centre, randomized, open-label trial focusing on high-risk patients with early-stage breast cancer. The trial has two main phases a surveillance phase and a treatment phase. During the surveillance phase, patients receive ctDNA testing every three months for up to three years to monitor for molecular relapse. If ctDNA is detected without visible disease on imaging, patients enter the treatment phase, where they are randomly assigned to receive either standard endocrine therapy or a combination of palbociclib and fulvestrant for up to 24 months. Palbociclib is taken orally daily for 21 days of each 28-day cycle, while fulvestrant is given as intramuscular injections on specific days of each cycle. Imaging is performed every six months to check for overt disease. Participants undergo regular blood tests for ctDNA monitoring during the surveillance phase and receive clinical assessments, imaging scans, and quality of life questionnaires during the treatment phase. Researchers measure the incidence of positive ctDNA results, relapse-free survival, and monitor adverse events. The total follow-up for relapse-free survival extends up to 60 months from randomization, while safety and quality of life are assessed up to 24 months. If macroscopic disease appears, participants stop trial treatment and receive standard care outside the study.

Age: 18Years +All GendersPhase 2
49 locations
A

Actively Recruiting

Researchers are studying patients with community-acquired pneumonia who need oxygen therapy due to acute respiratory distress and low blood oxygen levels. This research aims to see if placing patients in a prone position lying face down while they receive nasal high flow oxygen can reduce the need for intubation and improve outcomes. The study particularly excludes patients with COVID-19 and focuses on non-COVID pneumonia cases. Participants will be randomly assigned to one of two groups. One group will be encouraged and assisted to lie in the prone position for at least 8 hours per day in multiple sessions, aiming for up to 16 hours if tolerated. The other group will receive usual care with nasal high flow oxygen therapy but no prone positioning. Both groups will have oxygen levels monitored and care adjusted to maintain target oxygen saturation. During the study, patients will be observed for intubation rates within 28 days, comfort levels during prone positioning, oxygenation changes, time to escalation of breathing support, and overall outcomes including mortality up to 90 days. Safety measures like skin and infection monitoring will also be recorded. Quality of life will be assessed at 90 days and 5 years, with nursing workload tracked within the first day after randomization.

Age: 18Years +All GendersPhase Not Applicable
38 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.

Age: 40Years - 80YearsAll GendersPhase 3
281 locations
S

Actively Recruiting

Researchers are investigating treatments for patients with hormone receptor-positive, HER2 low or ultralow metastatic breast cancer who are undergoing first-line therapy with a CDK46 inhibitor combined with an aromatase inhibitor or fulvestrant. This open-label, multicenter phase II study focuses on patients whose tumor DNA remains detectable in their blood after four weeks of standard therapy, aiming to evaluate progression-free survival using trastuzumab deruxtecan T-DXd treatment. Patients first enter a screening phase to confirm the presence of circulating tumor DNA after starting standard treatment. Those with persistent tumor DNA are enrolled in the treatment phase, where they receive trastuzumab deruxtecan as an intravenous injection every three weeks at a dose of 5.4 mgkg. This single-group study evaluates how long patients live without disease progression while receiving the study drug. Participants undergo regular assessments including laboratory tests and imaging to monitor their disease status and safety during the study. Researchers measure progression-free survival as the primary outcome, along with overall survival, response rates, duration of response, clinical benefit, time to response, and treatment toxicity up to five years. Participants are followed for outcomes and safety throughout the study period, which may last several years.

Age: 18Years +All GendersPhase 2
40 locations
N

Actively Recruiting

This research evaluates whether non-invasive vagal stimulation can better prevent chemotherapy-induced nausea in breast cancer patients undergoing cyclophosphamide and anthracycline treatment. Chemotherapy-induced nausea remains common and negatively impacts quality of life despite existing medications. Non-invasive vagal stimulation is approved for other conditions like headache and gastroparesis and may reduce nausea. Participants receive standard antiemetic treatment along with either active non-invasive auricular vagal stimulation or a sham stimulation twice daily, starting the day before chemotherapy until four days after, during the first three chemotherapy cycles. The stimulation uses a transcutaneous auricular device to assess if adding this method improves nausea control compared to standard care alone. Throughout the study, participants are monitored for nausea occurrence after each chemotherapy cycle, vomiting, use of rescue medications, emergency visits, hydration needs, and hospitalizations related to nausea. Quality of life questionnaires specific to breast cancer and general health are completed during the first three cycles. Safety and side effects related to vagal stimulation are also evaluated. The trial measures outcomes over up to 12 weeks, with primary focus on nausea after the first chemotherapy cycle.

Age: 18Years +All GendersPhase Not Applicable
8 locations
P

Actively Recruiting

Researchers are conducting a multicenter, phase 3, open-label study to evaluate treatments for patients with newly diagnosed Multiple Myeloma who are eligible for autologous stem cell transplantation ASCT. The study compares the effects of an experimental combination of elranatamab and lenalidomide against the current standard of care, including chemotherapy, ASCT, and maintenance therapies. The purpose is to assess if these new treatment approaches improve outcomes such as minimal residual disease MRD negativity and progression-free survival. Participants will first undergo induction therapy with four cycles of D-VRd daratumumab, bortezomib, lenalidomide, dexamethasone. Then, they will be randomly assigned to one of two consolidation therapies either standard treatment with high-dose chemotherapy and ASCT followed by D-VRd consolidation, or an experimental consolidation with elranatamab and lenalidomide. After consolidation, patients are re-randomized into maintenance therapy groups receiving either daratumumab plus lenalidomide or elranatamab monotherapy for approximately two years, with treatment adjustments based on MRD status. Throughout the study, participants will have scheduled visits for treatment administration, monitoring, and various assessments including blood tests, imaging, and quality of life questionnaires. Researchers will measure key outcomes such as MRD negativity rates, progression-free survival, overall survival, safety, and tolerability over several years. The study also tracks health-related quality of life and adverse events during induction, consolidation, and maintenance phases, with follow-up extending up to 11 years.

Age: 18Years - 69YearsAll GendersPhase 3
69 locations
S

Actively Recruiting

Schizophrenia, affecting about 0.7% of the population, often leads to poor insight and medication compliance, resulting in relapses and a reduced quality of life. Researchers are evaluating an individual early psychoeducation program called PEPITS for inpatients with schizophrenia or related disorders. The study aims to see if PEPITS can reduce relapses, improve medication adherence and insight, and enhance quality of life. The PEPITS program is delivered by nurses during the initial hospitalization phase and consists of three parts an introduction session, sessions focused on understanding the illness and care, and sessions on recovery and building coping skills. Participants are randomly assigned to either the PEPITS program or to usual psychiatric care without PEPITS. Participants will be monitored from the start of the study until one year after randomization to assess changes in insight, quality of life, and medication compliance. Additional evaluations include quality of life and psychological well-being at work, job satisfaction, self-efficacy, and work commitment over six months. The study involves regular assessments to track these outcomes and better understand the programs impact.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
11 locations
F

Actively Recruiting

Researchers are studying patients with advanced cutaneous squamous cell carcinoma cSCC, a skin cancer with rising incidence and evolving treatment options. The study aims to describe how systemic therapies are used long-term in real-life settings for patients receiving treatments as curative, adjuvant, or neoadjuvant. This observational study collects data to better understand patient characteristics, treatment use, effectiveness, and safety. The study involves collecting information on patients starting first-line systemic therapy for cSCC from January 2020 onward. It includes both a retrospective phase and a prospective phase, gathering data from about 30 centers in France. Treatments studied include systemic drug therapies given with different intentions such as curative, adjuvant, or neoadjuvant. There is no intervention or randomization the study observes real-world treatment practices and changes over time. Participants are followed long term, with an average follow-up of 5 years to monitor treatment frequency, duration, and outcomes like response rates and survival. Researchers collect baseline patient data at diagnosis and track effectiveness and safety of therapies over time. The study also aims to identify new factors that predict treatment response or side effects. Data collection includes clinical characteristics and treatment details, contributing to a national database for cSCC management.

Age: 18Years +All Genders
29 locations

1-10 of 18

1